• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Dermatomycoses - Pipeline Review, H2 2012 Product Image

Dermatomycoses - Pipeline Review, H2 2012

  • Published: November 2012
  • 44 pages
  • Global Markets Direct

Dermatomycoses – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dermatomycoses - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dermatomycoses, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatomycoses. Dermatomycoses - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dermatomycoses.
- A review of the Dermatomycoses products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Dermatomycoses Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Dermatomycoses 7
Dermatomycoses Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Dermatomycoses Therapeutics – Products under Development by Companies 15
Companies Involved in Dermatomycoses Therapeutics Development 16
Valeant Pharmaceuticals International 16
Stiefel Laboratories, Inc. 17
Quinnova Pharmaceuticals, Inc. 18
Helix BioMedix, Inc. 19
Almirall, S.A. 20
Anacor Pharmaceuticals, Inc. 21
Nitric Biotherapeutics, Inc. 22
Laboratorio Teuto Brasileiro 23
Dermatomycoses – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
HB-1275 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IDP-113 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AN-2718 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
albaconazole - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LAS-41003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
nitric oxide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
econazole nitrate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tolnaftate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Dermatomycoses Therapeutics – Drug Profile Updates 39
Dermatomycoses Therapeutics - Dormant Products 40
Dermatomycoses – Product Development Milestones 41
Featured News & Press Releases 41
Sep 12, 2012: Topica Pharma Presents Findings From Phase I/IIa Trial Of Luliconazole Solution In Onychomycosis At ICAAC 2012 41
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel 41
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel 42
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77% 42
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77% 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Dermatomycoses, H2 2012 7
Products under Development for Dermatomycoses – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Valeant Pharmaceuticals International, H2 2012 16
Stiefel Laboratories, Inc., H2 2012 17
Quinnova Pharmaceuticals, Inc., H2 2012 18
Helix BioMedix, Inc., H2 2012 19
Almirall, S.A., H2 2012 20
Anacor Pharmaceuticals, Inc., H2 2012 21
Nitric Biotherapeutics, Inc., H2 2012 22
Laboratorio Teuto Brasileiro, H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Dermatomycoses Therapeutics – Drug Profile Updates 39
Dermatomycoses Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Dermatomycoses, H2 2012 7
Products under Development for Dermatomycoses – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos